leisure time -WSS

leisure time

author：knowledge 2025-09-27 23:33:30 - browse：7

Telehealth menopause treatment options displayed on cellphones emerging from a crack in the ground. -- health tech coverage from STAT — Molly Ferguson for STAT

At the turn of the century, nearly 18 million women in the United States were battling hot flashes, night sweats, and other symptoms of menopause with hormones. But in 2002, the therapy went into a free-fall when a landmark trial suggested treating menopause with estrogen and progesterone increased the risk of breast cancer and cardiovascular disease. The study was shut down early — and a year later, prescriptions had plummeted to nearly half what they had been in 2001.

More than two decades later, menopause experts have come to think about the results of the trial very differently. Newer research points to more benefits than risks for many healthy women under 60 treating menopause symptoms with hormone therapy. But many women who are good fits still aren’t getting treatment. “The pendulum has been slowly — too slowly — swinging back,” said OB-GYN Mike Green, chief medical officer of menopause telehealth company Winona.

Winona is part of a new generation of virtual-first health care companies aiming to give that pendulum a push. In the last five years, more than a dozen telehealth companies have started up to serve women in and approaching menopause, including with hormone therapy.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Dobbs anniversary: the lost opportunity of abortion as health care
Next article： Europe sees delivery challenges ahead on Alzheimer's therapies

leisure time

WSS

4 killed in mass shooting in Georgia, shooter remains on the loose: Police

Eli Lilly to acquire Versanis in heated race for weight loss drugs

Manchin, Huntsman team up to talk platform for 'unity' ticket that could run in 2024

EU regulator recommends expanding Mounjaro approval to obesity

J&J expands global access to TB drug amid advocacy campaign

Medicare Advantage today, explained in one chart

hotspot

leisure time

explore

BioMarin wins approval for gene therapy to treat hemophilia A

Europe sees delivery challenges ahead on Alzheimer's therapies

How to save PrEP access — and even expand it

Readout LOUD podcast: Biotech layoffs, stock slump, 2024 preview

Bright Health sells Medicare Advantage business to Molina

Prior authorization will have to move faster under new Biden rule

Wildfire smoke exposes gaps in outdoor worker protections

Care demand spikes challenge UnitedHealth’s provider arm

Trump demands the U.S. pay no more for drugs than other countries … again

Elon Musk says Twitter has 'negative cash flow' and 'heavy debt'

Wikipedia

eGenesis tests gene

Georgia court denies Trump's request to quash DA's 2020 election probe

Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

Mike Pence clashes with Tucker Carlson in Iowa

Eli Lilly to acquire Versanis in heated race for weight loss drugs

AI generated plenty of interest at JPM but not a lot of trust

Wikipedia

hotspot

leisure time

entertainment